BARDEX IC BROCHURE

It’s up to you to make a difference - 80% of all nosocomial UTIs are CAUTIs 1
You can make a difference
• Switching from standard catheters to silver alloy-coated catheters significantly reduces the risk of CAUTIs
• Using the Bard Comprehensive Care Foley Tray ensures all the items you need are together in one convenient pack
8,18
Bard Bardex I.C. Catheter Comprehensive Care Foley Trays
®
®
Relea sing tim e to ca r e for p a ti ents
®
Adopting silver alloy catheters is a proven solution
• Bardex® I.C. Foley Catheters with Bacti-Guard * silver alloy coating and Bard Hydrogel have a level one
recommendation from the UK Department of Health and are recognised by the epic guidelines
®
®
19
24
The efficacy of Bardex i.c. Foley Catheters is supported by a wealth of clinical evidence
®
• More than 30 studies have shown a reduction in incidence of CAUTIs with Bardex I.C. Foley Catheters
®
The best
just got
better
19
25
Ordering Information
Bardex I.C. Foley Catheters
®
Product Code
Bardex I.C. Aquafil with Bacti-Guard *
Silver Alloy Coating and Bard Hydrogel
Foley Catheters with 10mL prefilled
syringe of sterile water
®
®
®
®
Bardex I.C. Foley Tray - Hospital
NHS SC
Code**
Product Code
(Female Length)
NHS SC
Code**
Product Code
(Standard Length)
236512UKS
236514UKS
236516UKS
236518UKS
236520UKS
236522UKS
236524UKS
FSS370
FSS372
FSS374
FSS375
FSS377
FSS378
FSS381
236912UKS
236914UKS
236916UKS
FSS457
FSS458
FSS459
D236512S
D236514S
D236516S
D236518S
D236520S
D236522S
PIP Code
(Standard Length)
Product Code
PIP Code
(Female Length)
319-0758
319-0766
319-0774
319-0782
319-0790
319-0808
D236912S
D236914S
D236916S
319-5062
319-5070
319-5088
®
Collection System
Product Code
NHS SC Code**
(Standard Length)
Bardex I.C. Foley Catheter with
Bacti-Guard * Silver Alloy Coating
and Bard Hydrogel
®
®
Preconnected to Urinemeter
®
Preconnected to 2 Litre Bed Bag
Image shows
Hospital Foley
Tray with 2 litre
Bed Bag
Preconnected to 500mL Leg Bag
Bardex I.C. Foley Tray - Community
Product Code
NHS SC Code**
(Female Length)
TR2365UM12
TR2365UM14
TR2365UM16
TR23652L12
TR23652L14
TR23652L16
TR23655M12
TR23655M14
TR23655M16
FSS798
FSS799
FSS800
FSS801
FSS802
FSS803
FSS804
FSS805
FSS806
TR2369UM12
TR2369UM14
TR2369UM16
TR23692L12
TR23692L14
TR23692L16
TR23695M12
TR23695M14
TR23695M16
FSS807
FSS808
FSS809
FSS810
FSS811
FSS813
FSS814
FSS815
FSS816
Product Code
PIP Code
Product Code
PIP Code
®
Collection System
(Female Length)
(Standard Length)
Bardex I.C. Foley Catheter with
Bacti-Guard * Silver Alloy Coating
and Bard Hydrogel
®
®
Preconnected to Uriplan
Leg Bag D5S direct inlet
®
®
Preconnected to Uriplan
Leg Bag D5M 10cm inlet
®
Preconnected to Uriplan
Leg Bag D5L 30cm inlet
®
D23655S12
D23655S14
D23655S16
D23655M12
D23655M14
D23655M16
D23655L12
D23655L14
D23655L16
356-7997
356-8003
356-8029
356-7955
356-7963
356-7971
356-7922
356-7930
356-7948
D23695S12
D23695S14
D23695S16
D23695M12
D23695M14
D23695M16
D23695L12
D23695L14
D23695L16
356-8094
356-8102
356-8110
356-8060
356-8078
356-8086
356-8037
356-8045
356-8052
** Available through NHS Supply Chain and licensed for use up to 28 days
‘All in One’ anti-infective Foley catheterisation kit
All in One place, Only One price
• Encourages best practice
• Instant protection - for the clinician and the patient
• Cost effective
• Everything you need - more time with the patient
• Provides a sterile environment
• Available in Hospital and on the Drug Tariff
• Reduces risk of infection - clinically
proven anti-infection technology,
a true closed system
• Less waste
15
23
Isn't it time you changed?
Time FOR change
For further information on the product range please call 01293 606 786
References: 1.Plowman R, et al. An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters
to reduce the risk of urinary tract infections in catheterized patients. Journal of Hospital Infection (2001) 48: 33-42. 2. Maki DG, Tambyah PA.
Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001;7(2):342-347. 3. Pratt RJ, Pellowe C, Loveday HP et al. The
epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing
hospital-acquired infections. Department of Health (England). J Hosp Infect 2001;47 Suppl:S3-82. 4. Wagenlehner FM, Weidner W, Naber KG.
Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations.
J Hosp Infect 2005;60(3):191-200. 5. Plowman R, et al. The Socioeconomic Burden of Hospital Acquired Infection. Central Public Health
Laboratory and London School of Hygiene and Tropical Medicine. London, 1999. 6. www.dh.gov.uk/en/Healthcare/Qualityandproductivity/
QIPPworkstreams/DH_115447 7. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect
Control 2004 May;32(3):177-183. 8. Liedberg H. Catheter induced urethral inflammatory reaction and urinary tract infection. An experimental
and clinical study. Scand J Urol Nephrol Suppl 1989;124:1-43. 9. Liedberg H, Lundeberg T, Ekman P. Refinements in the coating of urethral
catheters reduces the incidence of catheter-associated bacteriuria. An experimental and clinical study. Eur Urol 1990;17(3):236-240. 10. Rupp
ME, Fitzgerald T, Marion N et al. Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect
Control 2004;32(8):445-450. 11. Verleyen P, De Ridder D, Van Poppel H et al. Clinical application of the Bardex IC Foley catheter. Eur Urol
1999;36(3):240-246. 12. Newton T, Still JM, Law E. A comparison of the effect of early insertion of standard latex and silver-impregnated latex
foley catheters on urinary tract infections in burn patients. Infect Control Hosp Epidemiol 2002;23(4):217-218. 13. Karchmer TB, Giannetta ET,
Muto CA et al. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med 2000;160(21):32943298. 14. Bologna RA, Tu LM, Polansky M et al. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates
in intensive care unit patients: a multicenter study. Urology 1999;54(6):982-987. 15. Gentry H, Cope S (2005) Using silver to reduce catheterassociated urinary tract infections. Nursing Standard. 19, 50, 51-54. Date of acceptance: June 20 2005. 16. Coral Seymour (2006). Audit of
catheter-associated UTI using silver alloy-coated Foley Catheters. British Journal of Nursing, 2006, Vol 15, No 11. Date of acceptance: April
2006. 17. Bard data on file. 18. Brosnahan J, Jull A, Tracy C. Types of urethral catheters for management of short-term voidi­­­ng problems
in hospitalised adults. Cochrane Database Syst Rev 2004(1):CD004013. 19. Health Protection Agency. Rapid Review Panel Reports: Bardex
IC - silver alloy coated hydrogel catheters. Available at http://www.hpa.org.uk/infections/topics_az/rapid_review/pdf/bardex2.pdf. 2004.
20. Schumm K, Lam TBL (2008). Types of urethral catheters for management of short-term voiding problems in hospitalised adults (Review) This
is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3
21. BARD. Data on file. 22. Ahearn DG, Grace DT, Jennings MJ et al. Effects of hydrogel/silver coatings on in vitro adhesion to catheters of bacteria
associated with urinary tract infections. Curr Microbiol 2000;41(2):120-125. 23. Madeo M, Roodhouse AJ, (2009) Reducing the risks associated
with urinary catheters. Nursing Standard. 23, 47-55. 24. Pellowe C, Pratt R, Loveday H et al. The epic project: updating the evidence base for
national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. A report with recommendations.
Br J Infect Control 2004;59(4):5,6,10-16. 21. ‘Clinical Data’ Compendium, Bard Limited. References: 25. Bard data on file.
Bard Limited, Forest House, Tilgate Forest Business Park, Brighton Road, Crawley, West Sussex RH11 9BP, UK
Telephone: 01293 527 888 Fax: 01293 552 428 Bard Customer Care: 01293 529 555
InfoLine: Telephone: 0800 591 783 Email: infoline@crbard.com
Please consult product labels and inserts for any indication, contraindications, hazards, warnings, cautions and directions for use. Bard, Aquafil, Bardex, Prescription Xpress and Uriplan are trademarks and/or registered trademarks of C.R. Bard, Inc.
*Bacti-Guard is a registered trademark of Bactiguard AB. The Foley Catheters included in the Bardex I.C. System contain Bacti-Guard silver alloy coating, which is licensed from Bactiguard AB. © 2011 C. R. BARD, Inc. All Rights Reserved 0411/2732
®
®
It's up to you to make a difference
Time
to
change
Urinary tract infections (UTIs) make up a large proportion of healthcare-associated
infections (HCAIs) in the UK – and four out of every five can be traced to
indwelling catheters. (Health Protection Agency, 2009)
Bardex I.C. anti-infective Foley Catheters work
Isn’t it time to change?
 h o w c a u t i s c a u se d a m a ge
®
• Urethra is damaged by friction, the passage of fluids
and the inflammatory response to bacteria7
DAMAGED
URETHRA
• T
he occurrence of UTI is 3.7 times greater in
patients catheterised with a standard catheter
than in patients catheterised with the Bardex I.C.
Foley Catheter with Bacti-Guard * Silver Alloy
coating and Bard Hydrogel
®
•
Catheter surfaces attract bacteria which develop into
a biofilm7 which means infection is harder to treat
This means there is massive scope for both improving the quality of patients’ lives
and saving precious healthcare resources by reducing the occurrence of UTIs.
Catheter-associated urinary tract infections
(cautis) cause immense problems for the
UK National Health Service (NHS)
 R educt io n o f CAUTIs is no w a prio rit y f o r t he NHS
• The Cochrane Review found a 40% reduction in symptomatic infection with silver alloy-coated
catheters versus standard catheters
18
®
®
17
• This may cause increased pain and discomfort
for your patients
BIOFILM
6
• T
he Bardex I.C. Foley Catheter was the first
device to receive a level one recommendation
from the Rapid Review Panel to tackle HAIs
®
19
“ The results suggest that the use of silver alloy indwelling catheters
for catheterising hospitalised adults short-term reduces the risk
of catheter acquired urinary tract infection.”
Inflammatory impact on cells of
urethral mucosa over 72 hours as
8†
measured on a 4-point scale
20
4.0
3.5
3.0
• Catheters are associated with 80%
of all nosocomial UTIs1
2.5
HYDROGEL
Bardex I.C. Foley Catheters fighting infection
and restoring patient comfort
®
2.0
• CAUTIs are the largest source of
antibiotic-resistant pathogens 2
1.5
1.0
0.5
CATHETER
• 1–4% of patients with CAUTI develop
secondary bacteraemia 3
Gold &
Palladium
0
Bardex® I.C.
*
• Unique combination of noble metals and hydrogel coating allows extended slow release of silver ions 21
SILVER
®
Hydrogel
Uncoated
Latex
+
• 13–30% of these patients die 3
Ag
Bacti-Guard
Silver Alloy
Ag
Urinary tract infections (UTIs)
are a major source of healthcare
associated infections (HCAIs)
As a result,
Department of Health
guidelines now make the
reduction of cautis
a priority
6
• The bacterial spectrum of nosocomial UTIs is
broad and antibiotic resistance is common4
Bardex i.c. Foley Catheters are proven more effective
than conventional catheters in reducing cautis
®
A wide range of clinical studies clearly show the advantages of Bardex® I.C. Foley Catheters
over conventional catheters.
Researcher
Study Size
Results
Liedberg, Lundeberg & Ekman, 1990
90 patients
80% reduction in CAUTIs
Rupp et al., 2004
>500,000 patient days
57% reduction in CAUTIs
180 patients
Bacteriuria reduced by 47%
Newton, Still & Law, 2002
1,757 patients
CAUTI/1000 patient days fell from 7.2 to 4.4
Karchmer et al., 2000
27,828 patients
Risk of CAUTI reduced by 32%
Bologna et al., 1999
5 ITUs, 108 beds
CAUTI/1000 patient days fell from 8.1 to 4.9
Gentry & Cope 2005
133 patients
33.5% reduction in CAUTIs
Seymour 2006
117 patients
Risk of CAUTI reduced by 71.2%
9
• CAUTIs cause between 21 to 45% of HAIs1
• Hospital-acquired UTIs cost the NHS
£124 million every year 5
• Every UTI costs an extra £1,327 per patient
and blocks a bed for an extra six days 5
10
Verleyen et al., 1999
11
12
13
14
15
16
4-point scale: 1. No oedema or other inflammatory sign 2. Mild oedema and loss of surface epithelium
3. Inflammatory infiltrate and epithelial loss 4. Inflammatory infiltrate, epithelial loss, exudate and haemorrhage.
†
UTIs CAN BE REDUCED WITH CORRECT CARE & EVIDENCE BASED TECHNOLOGY
• These silver ions inhibit biofilm formation and
reduce the risk of infection by 32% 13
+
Ag
Silver alloy catheters
• Preserve the integrity of the urethral
mucosa, preventing inflammation, loss
of epithelium and formation of biofilm
8,22
• Are proven effective in reducing infection compared with conventional catheters
10,11
• Biocompatible surface may reduce patient discomfort and aid speedy recovery
+